Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -646.93% is 109% below its 5-year average of -309.82%, around the middle of its 5-year range (-2211.76%–70.13%).
34.37% above its 12-month average of -985.69%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -610.24%.
EBITDA MARGIN
-646.93%
EBITDA MARGIN AVG TTM
-985.69%
EBITDA MARGIN AVG 3Y
-330.04%
EBITDA MARGIN AVG 5Y
-309.82%
EBITDA MARGIN AVG 10Y
-488.51%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+34.37%
CURRENT VS 3Y AVG
-96.02%
CURRENT VS 5Y AVG
-108.81%
CURRENT VS 10Y AVG
-32.43%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Alector, Inc.
Market Cap
$220.94M
EBITDA Margin
-646.93%
TTM Avg
-985.69%
3Y Avg
-330.04%
5Y Avg
-309.82%
Market Cap
$218.42M
EBITDA Margin
43.70%
TTM Avg
-4.00%
3Y Avg
-127.66%
5Y Avg
-437.76%
Market Cap
$236.56M
EBITDA Margin
-25.05%
TTM Avg
-32.88%
3Y Avg
-63.97%
5Y Avg
-61.52%
Market Cap
$239.45M
EBITDA Margin
-1029.09%
TTM Avg
-1029.09%
3Y Avg
-1029.09%
5Y Avg
-1029.09%
Market Cap
$244.25M
EBITDA Margin
10.49%
TTM Avg
1.20%
3Y Avg
-4.19%
5Y Avg
-40.04%
Market Cap
$248.21M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alector, Inc. (ALEC) | $220.94M | -646.93% | -985.69% | -330.04% | -309.82% |
| Compugen Ltd. (CGEN)vs › | $218.42M | 43.70% | -4.00% | -127.66% | -437.76% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $236.56M | -25.05% | -32.88% | -63.97% | -61.52% |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | -1029.09% | -1029.09% | -1029.09% | -1029.09% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $202.05M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | 10.49% | 1.20% | -4.19% | -40.04% |
| Galectin Therapeutics Inc. (GALT)vs › | $245.65M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.21M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | N/A | N/A | N/A | N/A |
Gross Margin
54.1%
EBITDA Margin
-646.9%
Operating Margin
-692.8%
Net Margin
-850.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -610.24% |
| 2026-03-31 | -2211.76% |
| 2025-12-31 | -598.16% |
| 2025-09-30 | -1115.67% |
| 2025-06-30 | -392.63% |
| 2025-03-31 | -1166.22% |
| 2024-12-31 | -9.53% |
| 2024-09-30 | -301.41% |
| 2024-06-30 | -287.24% |
| 2024-03-31 | -260.60% |
| 2023-12-31 | -297.53% |
| 2023-09-30 | -539.24% |
| 2023-06-30 | -3.78% |
| 2023-03-31 | -294.61% |
| 2022-12-31 | -374.27% |
| 2022-09-30 | -312.42% |
| 2022-06-30 | 13.60% |
| 2022-03-31 | -173.79% |
| 2021-12-31 | -386.84% |
| 2021-09-30 | 70.13% |
| 2021-06-30 | -818.15% |
| 2021-03-31 | -1243.16% |
| 2020-12-31 | -1056.15% |
| 2020-09-30 | -885.59% |
| 2020-06-30 | -1423.72% |
| 2020-03-31 | -566.62% |
| 2019-12-31 | -515.98% |
| 2019-09-30 | -1208.38% |
| 2019-06-30 | -374.18% |
| 2019-03-31 | -351.38% |
| 2018-12-31 | -204.93% |
| 2018-09-30 | -254.28% |
| 2018-06-30 | -168.50% |
| 2018-03-31 | -183.19% |
| 2017-12-31 | -314.71% |
| 2017-09-30 | -6479.74% |
| 2017-06-30 | -2382.03% |
| 2017-03-31 | -2382.03% |
